Rosuvastatin

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Retrieved on: 
Lunedì, Aprile 8, 2024
Vitamin E, Plasma, Rosuvastatin, Inflammation, Nitric oxide, Protein, EPA, Angiotensin, Endothelial dysfunction, Oxidative stress, Dietary supplement

These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.

Key Points: 
  • These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.
  • The beneficial effects of a high intensity statin and EPA on endothelial dysfunction may contribute to reduced atherothrombotic risk in outcome trials.
  • Elevated Lp(a) levels are an independent and causal risk factor for cardiovascular (CV) disease with limited treatments available.
  • The potent antioxidant actions of EPA may contribute to reduced CV events in REDUCE-IT, including among those subjects with elevated Lp(a).

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

Retrieved on: 
Lunedì, Novembre 13, 2023
Hepatitis, Arm, Safety, Randomness, SAN, ALT, FGF19, AASLD, Cirrhosis, Rosuvastatin, CRN, FDA, Non-alcoholic fatty liver disease, Metabolism, Liver, Therapy, Fatty liver disease, Prognosis, University, LSM, Manuscript, NGM, ELF, NASH, Fibrosis, Pharmaceutical industry, Medical imaging, Hepatology, Medicine, Patient

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today shared positive, comprehensive results from its Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated cirrhosis (liver fibrosis stage 4 or F4) due to NASH in an oral plenary presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.

Key Points: 
  • The ALPINE 4 data shared at AASLD The Liver Meeting follow positive topline results on the primary endpoint reported by NGM Bio in May 2023.
  • It’s gratifying to see the potential impact aldafermin is having on NASH progression and liver health in patients with F4 NASH.
  • This Phase 2b data set furthers our belief in aldafermin’s therapeutic potential,” said Hsiao D. Lieu, M.D., Chief Medical Officer at NGM Bio.
  • ELF measures direct markers of liver fibrosis and can be used to predict liver-related events in patients with NASH and compensated cirrhosis.

Homozygous Familial Hypercholesterolemia in the 7MM, 2023-2032: Epidemiology, Treatment Trends, Pipeline Activities, Expert Insights - ResearchAndMarkets.com

Retrieved on: 
Martedì, Agosto 29, 2023
Pharmaceutical, Health, Cardiology, Other Health, Prevalence, Rosuvastatin, Simvastatin, Epidemiology, FH, MTP, Atorvastatin, ANGPTL3, Patient, LDL, PCSK9, Improved, Population growth, Pharmaceutical industry

The "Homozygous Familial Hypercholesterolemia: Market Insights, Epidemiology and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Homozygous Familial Hypercholesterolemia: Market Insights, Epidemiology and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
  • The diagnosed prevalence of homozygous familial hypercholesterolemia (FH) has been on the rise in the US due to increased awareness and population growth.
  • Updated international diagnostic and clinical guidelines provide evidence-based therapeutic approaches and screening strategies for early identification of FH and homozygous FH.
  • The report offers a comprehensive understanding of homozygous FH epidemiology, treatment trends, pipeline activities, and expert insights.

EQS-News: APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023

Retrieved on: 
Giovedì, Giugno 29, 2023
Rosuvastatin, Ezetimibe, Smartphone, Acute coronary syndrome, CAD, AP, Prognosis, Tablet, Ticker, Patient, Physician, Gold, Coronary artery disease, CPO, Pharmaceutical industry

The online-based application enables physicians to selectively replace loose combinations (single drugs) with Single Pills according to the indication.

Key Points: 
  • The online-based application enables physicians to selectively replace loose combinations (single drugs) with Single Pills according to the indication.
  • Single Pills combine the established active ingredients in a single tablet in a daily single dose compared to loose combination therapy.
  • As an online physician assistance system, the free-of-charge Single Pill Finder shows possible Single Pill options for simplifying therapy for patients on polymedication.
  • Thomas Milz, Chief Product Officer (CPO) of APONTIS PHARMA AG: “With Rosazimib, APONTIS PHARMA has launched the first of at least three Single Pills announced for 2023.

CRN Responds to Cholesterol Study Wrongly Comparing Supplements to Prescription Drug Rosuvastatin

Retrieved on: 
Domenica, Novembre 6, 2022
Health, FDA, General Health, Research, Science, Cardiology, Vitamins, Supplements, American Heart Association, Exercise, Food, Association, Garlic, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Moyamoya disease, FDA, Triglyceride, Safety, Coronary artery disease, Hypertension, Quality control, CRN, Marketing, Misdirection, AstraZeneca, LDL, Dietary supplement, Risk, Health, Disease, SPORT, Council for Responsible Nutrition, Council, Rosuvastatin, Ethics

CRN Senior Vice President, Scientific and Regulatory Affairs Andrea Wong, Ph.D., put the results into context, explaining:

Key Points: 
  • CRN Senior Vice President, Scientific and Regulatory Affairs Andrea Wong, Ph.D., put the results into context, explaining:
    SPORT completely misses the point of supplementation by comparing the effects of a prescription drug to dietary supplements in a short-term study.
  • Dietary supplements are not intended to be quick fixes and their effects may not be revealed during the course of a study that only spans four weeks, particularly on a multifactorial condition like high cholesterol.
  • Its as if the study was set up for misdirection and failure of the supplements.
  • While all the supplements included in the study are well-recognized for their benefits related to heart health, only three are marketed for their cholesterol lowering benefits.

Xeter Outdoor Announces Spark: The Modular-Designed Outdoor Light That Can Transform for Different Scenarios

Retrieved on: 
Lunedì, Ottobre 10, 2022
GLOBE, Headache, Camping, Scalp, Kickstarter, Rosuvastatin, Light, Lighting, Rotation, Spark

NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Xeter is a startup brand that renovates traditional outdoor equipment to make them fit modern outdoor activities.

Key Points: 
  • NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Xeter is a startup brand that renovates traditional outdoor equipment to make them fit modern outdoor activities.
  • The idea comes from Xeter team members' daily experiences carrying a variety of lighting for camping - the flashlight, headlamp, bike light, lantern, and so forth.
  • With the push & pull design, consumers can adjust Spark's focus for both nearby area illumination and long-distance observation, depending on their need.
  • With the bike mount, consumers will be able to ride with a 400-lumens bike light and 360 degrees rotation for illumination.

Alnylam Announces New Management Appointments

Retrieved on: 
Mercoledì, Settembre 21, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Nexium, Therapy, Gene silencing, RNA interference, Sirna, Twitter, RNA transfection, Alexion Pharmaceuticals, Nobel Prize, Rosuvastatin, LinkedIn, Compliance, Cognizant, Takeda Pharmaceutical Company, Nobel Prize in Physiology or Medicine, Merck Serono, Physiology, Patient, IPO, Oncology, Finance, Instagram, Biology, Valuation, Cell, AstraZeneca, Nasdaq, Medication, Novartis, General manager, Hess Corporation, Drug development, Science, RNA, Biotechnology, Corporate development, Bachelor of Medicine, Bachelor of Surgery, Pfizer, Interferon beta-1a, Pharmaceutical industry, Alnylam Pharmaceuticals, Esomeprazole, Takeda, Medicine

In each case, their expertise will be invaluable as we continue to execute on our Alnylam P5x25 strategy, said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam.

Key Points: 
  • In each case, their expertise will be invaluable as we continue to execute on our Alnylam P5x25 strategy, said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam.
  • He joins Alnylam from Alexion Pharmaceuticals where he served as the Head of Compliance.
  • Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.
  • For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam , on LinkedIn , or on Instagram .

Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

Retrieved on: 
Lunedì, Luglio 18, 2022
Other Health, Research, Managed Care, General Health, Pharmaceutical, Consumer, Clinical Trials, Science, Women, Biotechnology, Other Science, Health, Half-life, History, Recurrence, CEO, Woman, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NOT, VVC, Communication, Person, Salpingoophorectomy, Capsule, Inflammation, Vaginal discharge, Food, Technology, Hypersensitivity, Insurance, Infertility, BCRP, Medication, Scott Richter, Incidence, Hysterectomy, Fetus, Commonwealth, Pain, Risk, Urination, Fungus, Enzyme, Candidiasis, Rosuvastatin, CYP51, FDA, Irritation, Toxicity, Education, CYP, Achievement, Pharmaceutical industry, Birth control

Potential appropriate patients for VIVJOA are women with RVVC who are postmenopausal or are permanently infertile due to a surgical procedure or for other reasons/conditions.

Key Points: 
  • Potential appropriate patients for VIVJOA are women with RVVC who are postmenopausal or are permanently infertile due to a surgical procedure or for other reasons/conditions.
  • To support effective two-way communication between patients and healthcare providers, we will encourage patients to ask their doctor if VIVJOA is right for them.
  • RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and defined as three or more symptomatic acute episodes of yeast infection in 12 months.
  • Mycovia Pharmaceuticals is an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies.

Mycovia Pharmaceuticals Announces Positive New Clinical Findings Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC)

Retrieved on: 
Mercoledì, Giugno 22, 2022
Science, Women, Research, Pharmaceutical, Managed Care, Health, Consumer, Clinical Trials, Candidiasis, Population, Half-life, Hypersensitivity, FDA, Vaginal discharge, Irritation, Inflammation, Person, Scott Richter, Infertility, Enzyme, CYP, Capsule, Recurrence, Urination, Medication, NOT, Commonwealth, Disease, Rosuvastatin, Pain, Fungus, Korea Disease Control and Prevention Agency, VVC, History, Incidence, CYP51, Patient, Doctor of Philosophy, BCRP, Salpingoophorectomy, Toxicity, Hysterectomy, Center, Woman, Risk, Fetus, Pharmaceutical industry, Birth control

Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today shared topline results from evaluating VIVJOA (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC).

Key Points: 
  • Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today shared topline results from evaluating VIVJOA (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC).
  • Of the 71 patients enrolled in the observational extension study, 85% completed 96 weeks without a recurrent VVC episode.
  • The authors concluded that VIVJOA may play an important role in providing long-term reduction in the incidence of disease recurrence for women with RVVC.
  • VIVJOA (oteseconazole) capsules is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

Mycovia Pharmaceuticals to Host Product Theater for VIVJOA™ (oteseconazole) During 2022 American College of Obstetricians and Gynecologists Annual Meeting

Retrieved on: 
Giovedì, Maggio 5, 2022
Research, Women, Infectious Diseases, FDA, Clinical Trials, General Health, Pharmaceutical, Consumer, Health, Science, BCRP, PDT, Specialization, Fetus, American College, Wayne, NOT, Woman, Toxicity, Rosuvastatin, ACOG, Medicine, Fungus, Infertility, Patient, Wayne State University School of Medicine, Half-life, Animal, Risk, FDA, Person, Hypersensitivity, Candidiasis, Incidence, Salpingoophorectomy, Scott Richter, Human, Enzyme, Center, Commonwealth, History, Adult, Salon, CYP51, Korea Disease Control and Prevention Agency, Dean, Medication, University School, Azole, CYP, American College of Obstetricians and Gynecologists, Hysterectomy, Recurrence, Pharmaceutical industry, Dietary supplement, Birth control, Gynaecology

Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company, will sponsor a product theater showcase for its recently FDA-approved VIVJOA (oteseconazole capsules), during the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting.

Key Points: 
  • Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company, will sponsor a product theater showcase for its recently FDA-approved VIVJOA (oteseconazole capsules), during the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting.
  • The session will be held at Salon 1 AB and open to all meeting attendees.
  • RVVC is a distinct condition from vulvovaginal candidiasis, and until recently, there have been no FDA-approved medications specifically indicated for it.
  • Nearly 75% of all adult women will have at least one yeast infection in their lifetime, with approximately half experiencing a recurrence.